2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171896
    A28-C6B2 98%
    A28-C6B2 is an ionizable cationic lipid with a pKa of 6.43, and can be used to generate lipid nanoparticles (LNPs) for mRNA delivery in vivo. A28-C6B2 can be studied in research for enhancing the selective delivery of mRNA to the spleen, particularly to antigen-presenting cells.
    A28-C6B2
  • HY-171897
    E10i-494 3031773-77-7 98%
    E10i-494 is an ionizable cationic branched endosomal disruptor (BEND) lipid. E10i-494 can be used to generate lipid nanoparticles (LNPs) for mRNA delivery in vitro. E10i-494 can enhance transfection efficiency.
    E10i-494
  • HY-171898
    Lipid I97 3046404-81-0 98%
    Lipid I97 is an ionizable lipid derived from vitamin B5 (pKa = 6.23). Lipid I97 can be used to generate lipid nanoparticles (LNPs) for mRNA delivery in vivo. Lipid I97 can be studied in research for enhancing mRNA transfection efficiency and long-term stability as well as formulation of mRNA vaccines.
    Lipid I97
  • HY-171900
    Lipid 114 98%
    Lipid 114 is an ionizable cationic lipid with a pKa of approximately 6.8. Lipid 114 can be used to generate lipid nanoparticles (LNP) to deliver siRNA in vitro as well as in vivo. Lipid 114 LNPs encapsulating siRNA that targets IL-1β can reduce IL-1β expression in macrophages. Lipid 114 LNPs encapsulating siRNA that targets IL-1β also reduces hepatic and renal expression of IL-1β, as well as decreasing hepatic inflammation in mouse model with LPS-induced acute liver failure.
    Lipid 114
  • HY-171927
    Lipid 12T-O14 3081873-30-2
    Lipid 12T-O14 is a lipid nanoparticle. 12T-O14 facilitates local mRNA vaccine and systemic mRNA agent delivery.
    Lipid 12T-O14
  • HY-171984
    514O6,10 2863553-06-2 98%
    514O6,10 is an ionizable lipidoid containing a branched-tail. 514O6,10 can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to natural killer and dendritic cells within the lung. 514O6,10 can be used for the RNA therapies for lung diseases associated with immune cell dysregulation, including cancer, viral infections, and autoimmune disorders research.
    514O6,10
  • HY-172087
    VDR agonist 3 3110217-32-5 98%
    VDR agonist 3 (Compound E15) is a potent vitamin D receptor (VDR) agonist. VDR agonist 3 can effectively inhibit HSC activation through VDR. VDR agonist 3 significantly reduces liver fibrosis without causing hypercalcemia in a CCl4-induced mouse liver fibrosis model.
    VDR agonist 3
  • HY-172090
    MASP-2-IN-1 3103336-29-1 98%
    MASP-2-IN-1 (Compound 77) is a selective MASP-2 inhibitor with an IC50 of 0.0114 μM, and an IC50 of 13.2 μM against MASP-3. MASP-2-IN-1 inhibits the catalytic activity of MASP-2 in the lectin complement pathway. MASP-2-IN-1 is applicable to the research of immune diseases.
    MASP-2-IN-1
  • HY-172099
    EP4 receptor agonist 3 634193-29-6 98%
    EP4 receptor agonist 3 is an EP4 receptor agonist that can be used in the study of colitis models in mice with DSS.
    EP4 receptor agonist 3
  • HY-172102
    NLRP3-IN-68 98%
    NLRP3-IN-68 (Compound 2d) is a 1,3,4-oxadiazole derivative. NLRP3-IN-68 has strong anti-inflammatory and antioxidant activities, which can inhibit inflammatory cytokines secretion, iNOS expression and NLRP3 inflammasome activation. NLRP3-IN-68 can be used in the research of anti-inflammatory drugs.
    NLRP3-IN-68
  • HY-172105
    Anti-NASH agent 2 3028778-28-8 98%
    Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models.
    Anti-NASH agent 2
  • HY-172107
    HPK1-IN-56 2901054-39-3 98%
    HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody.
    HPK1-IN-56
  • HY-172133
    HDAC3-IN-6 3070532-72-5 98%
    HDAC3-IN-6 (Compound SC26) is a selective HDAC3 inhibitor with an IC50 of 53 nM. HDAC3-IN-6 dose-dependently induces the expression of PD-L1. HDAC3-IN-6 induces more pronounced Apoptosis and production of ROS. HDAC3-IN-6 exhibits high antitumor efficacy against colorectal cancer.
    HDAC3-IN-6
  • HY-172134
    NLRP3-IN-70 1997362-01-2 98%
    NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis.
    NLRP3-IN-70
  • HY-172135
    PDE4-IN-26 98%
    PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases.
    PDE4-IN-26
  • HY-172148
    Itaconic acid prodrug-1 2641132-66-1 98%
    Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid (HY-Y0520) that efficiently delivers the active ingredient Itaconic acid to skin tissue following oral administration. Itaconic acid prodrug-1 possesses immunomodulatory properties, significantly inhibiting Poly(I:C)/IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 can be utilized for the research of alopecia areata and other inflammatory skin diseases.
    Itaconic acid prodrug-1
  • HY-172161
    CCR6 antagonist 2 98%
    CCR6 antagonist 2 (Compound 20c) is the antagonist for CCR6 with a Ki of 1.1 nM. CCR6 antagonist 2 inhibits CCL20-induced calcium ion influx (IC50 = 4.9 nM), inhibits the chemotactic migration of CCR6+ T cells (IC50 = 190 nM).
    CCR6 antagonist 2
  • HY-172169
    PPARγ-IN-5 3038323-12-2 98%
    PPARγ-IN-5 (Compound A3) is the inhibitor for PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPARγ-IN-5 can be used in research of non-alcoholic fatty liver disease.
    PPARγ-IN-5
  • HY-172193
    UBD1031 98%
    UBD1031 (SGC-UBD1031) is a selective USP16/HDAC6-UBD antagonist with a human USP16-UBD IC50 of 10.6 μM, KD value of 48 nM, and a human HDAC6-UBD KD of 16 nM. UBD1031 disrupts ISG15 C-terminus interactions with USP16-UBD and HDAC6-UBD, and exhibits cooperative inhibition of full-length USP16 deubiquitinase activity via USP16-UBD binding. UBD1031 can be used in research on cancer, autoimmune diseases, and Down syndrome.
    UBD1031
  • HY-172200
    PD-L1/HDAC6-IN-1 2834094-36-7 98%
    PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma.
    PD-L1/HDAC6-IN-1
Cat. No. Product Name / Synonyms Application Reactivity